Epigenomics' Preliminary 2013 Revenues Improve 60 Percent | GenomeWeb

NEW YORK (GenomeWeb News) – Epigenomics today announced preliminary revenue growth of 60 percent for full-year 2013.

Revenues for 2013 increased to €1.6 million ($2.2 million) from €1.0 million in 2012 on a strategic collaboration with BioChain in China and increased R&D service fees, the firm said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Biomedical research projects are generating a ton of data that still needs to be analyzed, NPR reports.

Theranos is retiring some of its board members, including Henry Kissinger and George Shultz, Business Insider reports.

The heads of 29 scientific societies and some 2,300 researchers call on President-elect Donald Trump to rely on and support science in two separate letters.

In Science this week: genetically modified flu virus could be key to new live vaccines, and more.